Psychiatr. pro Praxi, 2010; 11(2): 66-69

Treatment of tobacco dependence in psychiatric ill patients

MUDr.Lenka Štěpánková1,2, MUDr.Eva Králíková, CSc.1,2
1 Centrum léčby závislosti na tabáku III. interní kliniky –, kliniky endokrinologie a metabolizmu 1. LF UK a VFN, Praha
2 Ústav hygieny a epidemiologie 1. LF UK a VFN, Praha

Among psychiatric patients smoking rates are 2–3 fold higher compared to the general population. In addition, they smoke more cigarettes/

day and inhale more intensively, have higher blood levels of tobacco smoke metabolites and their nicotine dependence is stronger.

This is all related to high smoking-related mortality and morbidity among patients with mental health problems.

Since treatment of tobacco dependence in psychiatric ill patients is specific, there are specific guidelines available in many countries.

Also the Czech Psychiatric Association of the Czech Medical Association introduced such guidelines in 2009. In this paper we summarize

recommendations based on the recent literature, on our own clinical experience, and on visit at Mayo Nicotine Dependence Centre, Mayo

Clinic, Rochester (USA) to give a basic scheme of short or intensive smoking cessation intervention in psychiatric patients.

Keywords: smoking, tobacco dependence, psychiatric patient

Published: March 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štěpánková L, Králíková E. Treatment of tobacco dependence in psychiatric ill patients. Psychiatr. praxi. 2010;11(2):66-69.
Download citation

References

  1. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: A population-based prevalence study. JAMA, 2000: 22-29; 284(20): 2606-2610. Go to original source... Go to PubMed...
  2. Farrell M, Howes S, Taylor C, et al. Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. Int Rev Psychiatry 2003; 15(1-2): 43-49. Go to original source... Go to PubMed...
  3. Breslau N. Psychiatric comorbidity of smoking and nicotine dependence. Behavior Genetics 1995; 25(2): 95-101. Go to original source... Go to PubMed...
  4. Malone KM, Waternaux Ch, Haas GL, et al. Cigarette Smoking, Suicidal Behavior, and Serotonin Function in Major Psychiatric Disorders. Am J Psychiatry 2003; 160: 773-779. Go to original source... Go to PubMed...
  5. Hughes J, Hatsukami DK, Mitchell JE, et al. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143: 993-997. Go to original source... Go to PubMed...
  6. Ereshefsky L, Jann MW, Saklad SR, et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biological Psychiatry 1985; 20(3): 329-332. Go to original source... Go to PubMed...
  7. McNeill A. Smoking and patient with mental health problems. Health Development Agency, UK, NHS 2004.
  8. Peto R, Lopez AD, Boreham J, Thun M. Mortality from Smoking in Developed Countries 1950-2000, 2nd edition, Oxford University Press, http://www.ctsu.ox.ac.uk/~tobacco/.
  9. Kalman D, Kim S, Digirolamo G, et al. Addressing tobacco use disorder in smokers in early remission from alcohol dependence: The case for integrating smoking cessation services in substance use disorder treatment programs. Clin Psychol Rev. 2009 Sep 1. doi: 10.1016/j.cpr.2009.08.009. Go to original source... Go to PubMed...
  10. Miller M, Hemenway D, Rimm E. Cigarettes and suicide: a prospective study of 50,000 men. Am J Public Health. 2000; 90(5): 768-773. Go to original source... Go to PubMed...
  11. Williams JM, Ziedonis D. Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav. 2004; 29(6): 1067-1083. Go to original source... Go to PubMed...
  12. Compton MT, Daumit GL, Druss BG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry 2006; 14(4): 212-222. Go to original source... Go to PubMed...
  13. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008 www.surgeongeneral.gov/tobacco.
  14. Shenassa ED, Graham AL, Burdzovic JA, Buka SL. Psychometric properties of the Wisconsin Inventory of Smoking Dependence Motives (WISDM-68): a replication and extension. Nicotine Tob Res. 2009; 11(8): 1002-1010. Epub 2009 Jun 19. Go to original source... Go to PubMed...
  15. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the FTQ. Brit. J Addiction 1991; 86: 1119-1127. Go to original source... Go to PubMed...
  16. World Health Organization Europe: Regulation of Nicotine Replacement Therapies: An Expert Consensus, Copenhagen, WHO, 2001.
  17. Jorenby DE, Hays JT, Rigotti NA, et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63. Go to original source... Go to PubMed...
  18. Tonstad S, Tonnesen P, Hajek P, et al. Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 64-71. Go to original source... Go to PubMed...
  19. Gonzales D, Rennard SI, Nides M, et al. Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55. Go to original source... Go to PubMed...
  20. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ, 2009; 339: b3805, Published 1 2009, doi: 10.1136/bmj.b3805. Go to original source... Go to PubMed...
  21. Pisinger Ch. Smoking cessation in psychiatry: Is there sufficient evidence to recommend smoking cessation activities? A review of the literature. Network of Health Promoting Hospitals in Denmark, Copenhagen, March 2007: 24.




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.